Cargando…
Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned
An important pathogenetic distinction in the classification of myeloproliferative neoplasms (MPNs) is the presence or absence of the BCR–ABL fusion gene, which encodes a unique oncogenic tyrosine kinase. The BCR–ABL fusion, caused by the formation of the Philadelphia chromosome (Ph) through transloc...
Autores principales: | Pinilla-Ibarz, Javier, Sweet, Kendra L, Corrales-Yepez, Gabriela M, Komrokji, Rami S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4986686/ https://www.ncbi.nlm.nih.gov/pubmed/27570458 http://dx.doi.org/10.2147/OTT.S102504 |
Ejemplares similares
-
Clinical advances in the management of chronic myelogenous leukemia: focus on bosutinib and patient considerations
por: Sweet, Kendra, et al.
Publicado: (2014) -
Biomarkers for determining the prognosis in chronic myelogenous leukemia
por: Sweet, Kendra, et al.
Publicado: (2013) -
The Tyrosine Kinase-Driven Networks of Novel Long Non-coding RNAs and Their Molecular Targets in Myeloproliferative Neoplasms
por: Wong, Nonthaphat Kent, et al.
Publicado: (2021) -
Myeloproliferative neoplasms
por: Cross, Nick
Publicado: (2019) -
Myeloproliferative neoplasms
por: Kiladjian, Jean-Jacques
Publicado: (2018)